



BIOCORP exhibits its connected device, Inspair™, during RDD in Lisbon

Issoire, France, May 7th, 2019, 08:00 am CEST – BIOCORP (FR0012788065 – ALCOR / PEA-PME eligible), French company specializing in the development and manufacturing of medical devices and smart drug delivery systems, announces its participation to the new edition of Respiratory Drug Delivery Conference taking place in Lisbon (Portugal) from May 7th to 10th.

Respiratory Drug Delivery summit is one of the largest and most focused international conference of its kind, featuring in-depth presentations and discussion of pioneering respiratory drug delivery science.

Hosted on the booth of its partner, LINDAL GROUP⁽¹⁾, BIOCORP exhibits its connected device: Inspair. This smart sensor, converting inhalers into connected devices, helps patients with asthma or chronic obstructive pulmonary diseases (COPD).

Inspair brings an innovative and effective response to the needs of these two pathologies: it acts directly on the treatment compliance and strengthens the connection between the patient and the medical staff, providing a real-time therapeutic follow-up. This smart sensor converts any pressurized metered dose inhaler into a connected device. Inspair records data related to daily inhalations, ensures the right preparation of the canister, assesses the coordination of actuation with inhalation and provides a useful guidance throughout different steps, mastering the inhalation technique.

On Wednesday, May 8th, Arnaud Guillet, Business Development Director, will animate a workshop dealing with "Using connected compliance monitoring solutions in the context of clinical trials for new respiratory medicines ". This session will feature a presentation of BIOCORP's technical solution with a live demonstration and introduce real-life cases.

(1) Refer to BIOCORP press release on December 12th, 2018

ABOUT BIOCORP

Founded in 2004 in Issoire (near Clermont-Ferrand), France, BIOCORP is a French company specializing in the development and manufacturing of medical devices and innovative drug delivery systems. It is listed as 'Innovative Company' by the French public investment bank Bpifrance. With over twenty years of experience and more than 30 manufactured products, BIOCORP is a key player in the industry, providing drug delivery solutions that meet the evolving needs of patients. Today, BIOCORP continues to innovate in medical plastics, its core business, and to market traditional devices (alternative to aluminum capsules, syringe and vial administration systems) that have been an important source of recurring income. Its solid expertise and capacity to innovate have allowed the company to develop new Internet-connected products, including Mallya™, a smart cap for pen injectors that captures injection data and automatically transmits data to a mobile app, helping patients to manage their treatment. The company has a team of 45 employees. BIOCORP is listed on Euronext since July 2015 (FR0012788065 – ALCOR).

For more information, please visit www.biocorpsys.com

Follow us on Twitter [@BIOCORPSystems](https://twitter.com/BIOCORPSystems)

BIOCORP Contacts

Jacques Gardette
CEO
investisseurs@biocorp.fr

Éric Dessertenne
Chief Operating Officer

Sylvaine Dessard
Marketing & Communication Director
rp@biocorp.fr
+ 33 (0)6 88 69 72 85